

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent	12383673
Kind Code	B2
Date of Patent	August 12, 2025
Inventor(s)	Kearns; Jacob et al.

Systems and methods for automated insulin delivery for diabetes therapy

Abstract

Disclosed herein are systems and methods for mitigating the risk of insulin stacking in automated insulin delivery systems. In AID systems configured to both automatically calculate insulin delivery based on glucose levels and receive manual programming of meal boluses configured to counteract carbohydrates in a meal, insulin stacking can result if the system automatically increases insulin delivery based on a rise in glucose levels in response to consumption of a meal and the user later programs a meal bolus for the meal. The risk of such double dosing is mitigated by the systems and methods disclosed herein by enabling the system to account for recent automated insulin increases when a meal bolus is programmed.

Inventors: Kearns; Jacob (San Diego, CA), Michaud; Michael (San Diego, CA), Kruse; Geoffrey A. (San Diego, CA), Ulrich; Thomas R. (Oceanside, CA), Harris; Paul (San Diego, CA), Leas; Scott (San Diego, CA), Dokken; Betsy (San Diego, CA), Marin; Garrett (San Diego, CA), Sherer; Nicholas (Escondido, CA)

Applicant: Tandem Diabetes Care, Inc. (San Diego, CA)

Family ID: 1000008751424

Assignee: Tandem Diabetes Care, Inc. (San Diego, CA)

Appl. No.: 18/136278

Filed: April 18, 2023

Prior Publication Data

Document Identifier	Publication Date
US 20240350728 A1	Oct. 24, 2024

Related U.S. Application Data

Publication Classification

Int. Cl.: **A61M5/172** (20060101); **A61B5/145** (20060101); **A61M5/142** (20060101); **G16H20/17** (20180101); **G16H20/60** (20180101)

U.S. Cl.:

CPC **A61M5/1723** (20130101); **A61B5/14532** (20130101); **G16H20/17** (20180101); **G16H20/60** (20180101); A61M2205/18 (20130101); A61M2205/3584 (20130101); A61M2205/3592 (20130101); A61M2205/505 (20130101); A61M2205/52 (20130101); A61M2230/201 (20130101)

Field of Classification Search

CPC: A61M (5/1723); A61M (2205/3584); A61M (2205/3592); A61M (2205/505); A61M (2205/52); A61M (2230/201); A61M (2205/3303); A61M (5/14244); A61M (5/142); A61M (2005/14208); A61M (5/14); A61M (5/168); A61M (5/172); A61M (2205/502); A61M (2230/20); A61M (2205/33); G16H (20/17)

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
4403984	12/1982	Ash	N/A	N/A
5792117	12/1997	Brown	N/A	N/A
6068615	12/1999	Brown et al.	N/A	N/A
6110148	12/1999	Brown et al.	N/A	N/A
6352523	12/2001	Brown et al.	N/A	N/A
6544212	12/2002	Galley et al.	N/A	N/A
7060059	12/2005	Keith et al.	N/A	N/A
7137951	12/2005	Pilarski	N/A	N/A
7231263	12/2006	Choi	N/A	N/A
7491187	12/2008	Van Den Berghe et al.	N/A	N/A
7590443	12/2008	Bharmi	N/A	N/A
7651845	12/2009	Doyle, III et al.	N/A	N/A
7670288	12/2009	Sher	N/A	N/A
7879026	12/2010	Estes et al.	N/A	N/A
8088098	12/2011	Yodfat et al.	N/A	N/A
8118782	12/2011	Remde	N/A	N/A
8246540	12/2011	Ginsberg	N/A	N/A
8452953	12/2012	Buck et al.	N/A	N/A
8467980	12/2012	Campbell et al.	N/A	N/A
8491566	12/2012	Ramey et al.	N/A	N/A
8517991	12/2012	Clemente	N/A	N/A
8545437	12/2012	Sakata et al.	N/A	N/A

8552880	12/2012	Kopp et al.	N/A	N/A
8556865	12/2012	Krulevitch et al.	N/A	N/A
8579879	12/2012	Palerm et al.	N/A	N/A
8622991	12/2013	Pesach et al.	N/A	N/A
8635054	12/2013	Brown	N/A	N/A
8687811	12/2013	Nierzwick et al.	N/A	N/A
8818782	12/2013	Thukral et al.	N/A	N/A
9089305	12/2014	Hovorka	N/A	N/A
9440025	12/2015	Kanderian, Jr. et al.	N/A	N/A
9477939	12/2015	Brown	N/A	N/A
9486171	12/2015	Saint	N/A	N/A
9486571	12/2015	Rosinko	N/A	N/A
9532737	12/2016	Karan et al.	N/A	N/A
9669160	12/2016	Harris et al.	N/A	N/A
9757510	12/2016	Finan	N/A	N/A
9833177	12/2016	Blomquist	N/A	N/A
9833571	12/2016	Budiman	N/A	N/A
9867937	12/2017	Saint et al.	N/A	N/A
9867953	12/2017	Rosinko	N/A	N/A
9937290	12/2017	Connelly et al.	N/A	N/A
10016561	12/2017	Saint et al.	N/A	N/A
10052049	12/2017	Blomquist et al.	N/A	N/A
10569016	12/2019	Rosinko	N/A	N/A
10726100	12/2019	Blomquist et al.	N/A	N/A
10872102	12/2019	Wei et al.	N/A	N/A
10943687	12/2020	Blomquist	N/A	N/A
10966608	12/2020	Bergstrom et al.	N/A	N/A
11024429	12/2020	Patek et al.	N/A	N/A
11097051	12/2020	Wu et al.	N/A	N/A
11116900	12/2020	Haider et al.	N/A	N/A
11116901	12/2020	Harris	N/A	N/A
11189373	12/2020	Schmidt et al.	N/A	N/A
11217339	12/2021	Blomquist	N/A	N/A
11224693	12/2021	Ulrich et al.	N/A	N/A
11246986	12/2021	Wilinska et al.	N/A	N/A
11291763	12/2021	Blomquist et al.	N/A	N/A
11376362	12/2021	Mazlish	N/A	N/A
11464908	12/2021	Michaud et al.	N/A	N/A
11607492	12/2022	Rosinko et al.	N/A	N/A
11654236	12/2022	Kearns et al.	N/A	N/A
11676694	12/2022	Kruse et al.	N/A	N/A
11749410	12/2022	Hayter et al.	N/A	N/A
11751779	12/2022	Kovatchev et al.	N/A	N/A
2003/0100863	12/2002	Shekalim	N/A	N/A
2003/0212379	12/2002	Bylund et al.	N/A	N/A
2005/0065760	12/2004	Murtfeldt et al.	N/A	N/A
2006/0132292	12/2005	Blomquist	N/A	N/A
2006/0276771	12/2005	Galley et al.	N/A	N/A
2007/0179434	12/2006	Weinert	600/504	G16H 20/10
2008/0071580	12/2007	Marcus et al.	N/A	N/A

2008/0171967	12/2007	Blomquist et al.	N/A	N/A
2008/0172027	12/2007	Blomquist	N/A	N/A
2008/0172030	12/2007	Blomquist	N/A	N/A
2009/0036753	12/2008	King	N/A	N/A
2010/0145262	12/2009	Bengtsson et al.	N/A	N/A
2010/0262117	12/2009	Magni et al.	N/A	N/A
2010/0331652	12/2009	Groll et al.	N/A	N/A
2011/0071464	12/2010	Palerm	N/A	N/A
2011/0098548	12/2010	Budiman et al.	N/A	N/A
2011/0205065	12/2010	Strachan et al.	N/A	N/A
2012/0245556	12/2011	Kovatchev et al.	N/A	N/A
2013/0110552	12/2012	Horiguchi et al.	N/A	N/A
2014/0333438	12/2013	Halff	N/A	N/A
2015/0119805	12/2014	Blomquist	N/A	N/A
2017/0035962	12/2016	Lecanu-Fayet et al.	N/A	N/A
2017/0189614	12/2016	Mazlish	N/A	A61M 5/1723
2018/0154077	12/2017	Davidson et al.	N/A	N/A
2018/0296757	12/2017	Finan	N/A	G16H 20/17
2019/0019571	12/2018	Breton et al.	N/A	N/A
2019/0099551	12/2018	Yodfat	N/A	A61M 5/16831
2019/0125969	12/2018	Montgomery et al.	N/A	N/A
2020/0368430	12/2019	Ulrich et al.	N/A	N/A
2021/0001044	12/2020	Michaud et al.	N/A	N/A
2021/0038134	12/2020	Steil et al.	N/A	N/A
2021/0113766	12/2020	Kearns et al.	N/A	N/A
2021/0313036	12/2020	Breton et al.	N/A	N/A
2021/0353857	12/2020	Ulrich et al.	N/A	N/A
2022/0047812	12/2021	Budiman et al.	N/A	N/A
2022/0062553	12/2021	Constantin et al.	N/A	N/A
2022/0101978	12/2021	Blomquist	N/A	N/A
2022/0233772	12/2021	Ulrich et al.	N/A	N/A
2022/0233773	12/2021	Rueda et al.	N/A	N/A
2022/0265927	12/2021	Harris et al.	N/A	N/A
2023/0001090	12/2022	Sloan et al.	N/A	N/A
2023/0034408	12/2022	Nichols et al.	N/A	N/A
2023/0037465	12/2022	Rueda et al.	N/A	N/A
2023/0040677	12/2022	Tran et al.	N/A	N/A
2023/0113755	12/2022	Lu et al.	N/A	N/A
2023/0148019	12/2022	Boss et al.	N/A	N/A
2023/0166037	12/2022	Ulrich et al.	N/A	N/A
2023/0277761	12/2022	Saint	N/A	N/A

Primary Examiner: Flick; Jason E

Attorney, Agent or Firm: Merchant & Gould, P.C.

Background/Summary

RELATED APPLICATION (1) This application is a continuation of application Ser. No. 16/952,478, filed Nov. 19, 2020, which claims the benefit of U.S. Provisional Application No. 62/939,015, filed Nov. 22, 2019, each of which is hereby fully incorporated herein by reference.

FIELD OF THE INVENTION

(1) The present invention relates generally to ambulatory infusion pumps and, more particularly, to operation of ambulatory infusion pumps in a closed-loop or semi-closed-loop fashion.

BACKGROUND OF THE INVENTION

(2) There are a wide variety of medical treatments that include the administration of a therapeutic fluid in precise, known amounts at predetermined intervals. Devices and methods exist that are directed to the delivery of such fluids, which may be liquids or gases, are known in the art.

(3) One category of such fluid delivery devices includes insulin injecting pumps developed for administering insulin to patients afflicted with type 1, or in some cases, type 2 diabetes. Some insulin injecting pumps are configured as portable or ambulatory infusion devices that can provide continuous subcutaneous insulin injection and/or infusion therapy as an alternative to multiple daily insulin injections via syringe or injector pen. Such ambulatory infusion pumps may be worn by the user, may use replaceable medicament cartridges, and may deliver other medicaments alone, or in combination with insulin. Such medicaments include glucagon, pramlintide, and the like. Examples of such pumps and various features associated therewith include those disclosed in U.S. Patent Publication Nos. 2013/0324928 and 2013/0053816 and U.S. Pat. Nos. 8,287,495; 8,573,027; 8,986,253; and 9,381,297, each of which is incorporated herein by reference in its entirety.

(4) Ambulatory infusion pumps for delivering insulin or other medicaments can be used in conjunction with blood glucose monitoring systems, such as continuous glucose monitoring (CGM) devices. A CGM device consists of a sensor placed under the patient's skin and affixed to the patient via an adhesive patch, a transmitter, and a monitor. A CGM device samples the patient's interstitial fluid periodically (e.g. once every 1-5 minutes) to estimate blood glucose levels over time. CGMs are advantageous because they provide more frequent insights into a user's blood glucose levels yet do not require a finger stick each time a reading is taken.

(5) Ambulatory infusion pumps may incorporate a CGM within the hardware of the pump or may communicate with a dedicated CGM directly via a wired connection or indirectly via a wireless connection using wireless data communication protocols to communicate with a separate device (e.g., a dedicated remote device or a smartphone). One example of integration of ambulatory infusion pumps with CGM devices is described in U.S. Patent Publication No. 2014/0276419, which is hereby incorporated by reference herein. Ambulatory infusion pumps typically allow the user or caregiver to adjust the amount of insulin or other medicament delivered by a basal rate or a bolus, based on blood glucose data obtained by a CGM device, and in some cases include the capability to automatically adjust such medicament delivery. For example, based on CGM readings, some ambulatory infusion pumps may automatically adjust or prompt the user to adjust the level of medicament being administered or planned for administration or, in cases of abnormally low blood glucose readings, reducing or temporarily ceasing insulin administration.

(6) In some cases, ambulatory insulin pumps may be configured to deliver insulin based on CGM data in a closed-loop or semi-closed-loop fashion. Some systems including these features may be referred to as automated insulin delivery (AID) systems or artificial pancreas systems because these systems serve to mimic biological functions of the pancreas for persons with diabetes.

(7) Some AID systems primarily deliver medicament automatically based on CGM readings, but also enable users to program meal boluses. Consumption of carbohydrates in a meal causes blood glucose to rise, which can be counteracted by insulin or other medicament delivered in a meal bolus. If a user delays in delivering the meal bolus, the user's blood glucose may begin to rise prior to the meal bolus being delivered. This can be problematic with AID systems that automatically deliver correction boluses (and/or increase a basal rate) based on CGM readings, because the

system may deliver a correction bolus in response to the CGM readings and the user then subsequently delivers a meal bolus. This “insulin stacking” resulting from two separate insulin deliveries intended to counteract the same rise in blood glucose can cause the user's blood glucose to drop to a low level.

SUMMARY OF THE INVENTION

(8) Disclosed herein are systems and methods for mitigating the risk of insulin stacking in automated insulin delivery systems. In AID systems configured to both automatically calculate insulin delivery based on glucose levels and receive manual programming of meal boluses configured to counteract carbohydrates in a meal, insulin stacking can result if the system automatically increases insulin delivery based on a rise in glucose levels in response to consumption of a meal and the user later programs a meal bolus for the meal. The risk of such double dosing is mitigated by the systems and methods disclosed herein by enabling the system to account for recent automated insulin increases when a meal bolus is programmed.

(9) In an embodiment, an ambulatory infusion pump system can include a pump mechanism configured to facilitate delivery of insulin to a user, a user interface, a communications device adapted to receive glucose levels from a continuous glucose monitor and a processor functionally linked to the pump mechanism, the user interface and the communications device. The processor can be configured to automatically calculate insulin doses with a closed loop delivery algorithm based on glucose levels received from the continuous glucose monitor. If user input is received through the user interface programming a meal bolus configured to deliver insulin to counteract carbohydrates consumed in a meal, the processor can determine if the meal bolus is programmed within a predetermined time of one or more automatically calculated insulin doses that increased an amount of insulin delivered to the user. The processor can then automatically modify the meal bolus if the meal bolus was programmed within the predetermined time of the automatically calculated insulin dose that increased the amount of insulin delivered to the user in order to reduce the possibility of insulin stacking.

(10) In an embodiment, an ambulatory infusion pump system can include a pump mechanism configured to facilitate delivery of insulin to a user, a user interface, a communications device adapted to receive glucose levels from a continuous glucose monitor and a processor functionally linked to the pump mechanism, the user interface and the communications device. The processor can be configured to receive user input through the user interface programming a meal bolus configured to deliver insulin to counteract carbohydrates consumed in a meal. The processor can then determine if a closed loop delivery algorithm calculated an increase in insulin based on glucose levels received from the continuous glucose monitor that was delivered within a predetermined time prior to programming of the meal bolus. The processor can automatically modify the meal bolus if the increase in insulin based on glucose levels received from the continuous glucose monitor was delivered within the predetermined time prior to programming of the meal bolus to reduce the possibility of insulin stacking.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The invention may be more completely understood in consideration of the following detailed description of various embodiments of the invention in connection with the accompanying drawings, in which:

(2) FIG. 1 is an embodiment of an ambulatory infusion pump for use with embodiments of the disclosure.

(3) FIG. 2 is a block diagram of the ambulatory infusion pump of FIG. 1.

(4) FIGS. 3A-3B are an alternate embodiment of an ambulatory infusion pump for use with

embodiments of the disclosure.

(5) FIG. 4 is an embodiment of a CGM for use with embodiments of the disclosure.

(6) FIG. 5 is a flowchart of a method of delivering medicament in automated insulin delivery systems according to an embodiment.

(7) FIG. 6 is a flowchart of a method of delivering medicament in automated insulin delivery systems according to an embodiment.

(8) While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.

DETAILED DESCRIPTION OF THE INVENTION

(9) The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.

(10) FIG. 1 depicts an example infusion pump that can be used in conjunction with one or more embodiments of the ambulatory infusion pump system of the present disclosure. Pump 12 includes a pumping or delivery mechanism and reservoir for delivering insulin or other medicament to a patient and an output/display 44. The output/display 44 may include an interactive and/or touch sensitive screen 46 having an input device such as, for example, a touch screen comprising a capacitive screen or a resistive screen. The pump 12 may additionally or instead include one or more of a keyboard, a microphone or other input devices known in the art for data entry, some or all of which may be separate from the display. The pump 12 may also include a capability to operatively couple to one or more other display devices such as a remote display (e.g., a dedicated remote display or a CGM display), a remote control device, or a consumer electronic device (e.g., laptop computer, personal computer, tablet computer, smartphone, electronic watch, electronic health or fitness monitor, or personal digital assistant). Further details regarding such pump devices can be found in U.S. Pat. No. 8,287,495, previously incorporated by reference above. It is to be appreciated that pump 12 may be optionally configured to deliver one or more additional or other medicaments to a patient.

(11) FIG. 2 illustrates a block diagram of some of the features that may be included within the housing 26 of pump 12. The pump 12 can include a processor 42 that controls the overall functions of the pump. The pump 12 may also include, e.g., a memory device 30, a transmitter/receiver 32, an alarm 34, a speaker 36, a clock/timer 38, an input device 40, a user interface suitable for accepting input and commands from a user such as a caregiver or patient, a drive mechanism 48, an estimator device 52 and a microphone (not pictured). One embodiment of a user interface is a graphical user interface (GUI) 60 having a touch sensitive screen 46 with input capability. In some embodiments, the processor 42 may communicate with one or more other processors within the pump 12 and/or one or more processors of other devices through the transmitter/receiver 32 such as a remote device (e.g., CGM device), a remote control device, or a consumer electronic device (e.g., laptop computer, personal computer, tablet computer, smartphone, electronic watch, electronic health or fitness monitor, or personal digital assistant). In some embodiments, the communication is effectuated wirelessly, by way of example only, via a near field communication (NFC) radio frequency (RF) transmitter or a transmitter operating according to a "Wi-Fi" or Bluetooth® protocol, Bluetooth® low energy protocol or the like. The processor 42 may also include programming to receive signals and/or other data from an input device, such as, by way of example, a pressure sensor, a temperature sensor, or the like.

(12) FIGS. 3A-3B depicts a second infusion pump that can be used in conjunction with one or more embodiments of the ambulatory infusion pump system of the present disclosure. Pump 102

includes a pump drive unit **118** and a medicament cartridge **116**. Pump **102** includes a processor that may communicate with one or more processors within the pump **102** and/or one or more processors of other devices such as a remote device (e.g., a CGM device), a remote control device, or a consumer electronic device (e.g., laptop computer, personal computer, tablet computer, smartphone, electronic watch, electronic health or fitness monitor, or personal digital assistant). The processor **42** may also include programming to receive signals and/or other data from an input device, such as, by way of example, a pressure sensor, a temperature sensor, or the like. Pump **102** also includes a processor that controls some or all of the operations of the pump. In some embodiments, pump **102** receive commands from a separate device for control of some or all of the operations of the pump. Such separate device can include, for example, a dedicated remote control device or a consumer electronic device such as a smartphone having a processor executing an application configured to enable the device to transmit operating commands to the processor of pump **102**. In some embodiments, processor can also transmit information to one or more separate devices, such as information pertaining to device parameters, alarms, reminders, pump status, etc. Such separate device can include any remote display, remote control device, or a consumer electronic device as described above. Pump **102** can also incorporate any or all of the features described with respect to pump **12** in FIG. **2**. In some embodiments, the communication is effectuated wirelessly, by way of example only, via a near field communication (NFC) radio frequency (RF) transmitter or a transmitter operating according to a “Wi-Fi” or Bluetooth® protocol, Bluetooth® low energy protocol or the like. Further details regarding such pumps can be found in U.S. Pat. No. 10,279,106 and U.S. Patent Publication Nos. 2016/0339172 and 2017/0049957, each of which is hereby incorporated herein by reference in its entirety.

(13) FIG. **4** depicts an example CGM system that can be used in conjunction with one or more embodiments of the ambulatory infusion pump system of the present disclosure. The CGM system includes a sensor **101**, a sensor probe **106**, a sensor body **108**, a receiver, and a monitor (receiver and monitor are depicted as device **100** in FIG. **4**). The sensor **101** is removably affixed to a user **104** and includes a sensor probe **106** configured for transcutaneous insertion into the user **104**. When placed, the sensor probe **106** reacts with the user's interstitial fluid which produces a signal that can be associated with the user's blood glucose level. The sensor **101** further includes a sensor body **108** that transmits data associated with the signal to the receiver **100** via wired or wireless connection (as represented by arrow line **112**). In preferred embodiments, the receiver **100** receives the transmitted data wirelessly by any suitable means of wireless communication. By way of example only, this wireless communication may include a near field communication (NFC) radio frequency (RF) transmitter or a transmitter operating according to a “Wi-Fi” or Bluetooth® protocol, Bluetooth® low energy protocol or the like. Further detail regarding such systems and definitions of related terms can be found in, e.g., U.S. Pat. Nos. 8,311,749, 7,711,402 and 7,497,827, each of which is hereby incorporated by reference in its entirety.

(14) With the infusion pump and CGM interfaced, the CGM can automatically transmit the CGM data to the pump. The pump can then use this data to automatically determine therapy parameters and suggest a therapy adjustment to the user or automatically deliver the therapy adjustment to the user. These therapy parameters including thresholds and target values can be stored in memory located in the pump or, if not located in the pump, stored in a separate location and accessible by the pump processor (e.g., “cloud” storage, a smartphone, a CGM, a dedicated controller, a computer, etc., any of which is accessible via a network connection). The pump processor can periodically and/or continually execute instructions for a checking function that accesses these data in memory, compares them with data received from the CGM and acts accordingly to adjust therapy. In further embodiments, rather than the pump determining the therapy parameters, the parameters can be determined by a separate device and transmitted to the pump for execution. In such embodiments, a separate device such as the CGM or a device in communication with the CGM, such as, for example, a smartphone, dedicated controller, electronic tablet, computer, etc.

can include a processor programmed to calculate therapy parameters based on the CGM data that then instruct the pump to provide therapy according to the calculated parameters.

(15) For example, if the CGM readings indicate that the user has or is predicted to have a high blood glucose level (hyperglycemia), the ambulatory infusion system can automatically calculate an insulin dose sufficient to reduce the user's blood glucose level below a threshold level or to a target level and automatically deliver the dose. Alternatively, the ambulatory infusion system can automatically suggest a change in therapy upon receiving the CGM readings such as an increased insulin basal rate or delivery of a bolus, but can require the user to accept the suggested change prior to delivery rather than automatically delivering the therapy adjustments.

(16) By way of further example, if the CGM readings indicate that the user has or is predicted to have a low blood glucose level (hypoglycemia), the ambulatory infusion system can, for example, automatically reduce or suspend a basal rate, suggest to the user to reduce a basal rate, automatically deliver or suggest that the user initiate the delivery of an amount of a substance such as, e.g., a hormone (glucagon) to raise the concentration of glucose in the blood, automatically suggest that the patient address the hypoglycemic condition as necessary (e.g., ingest carbohydrates), singly or in any desired combination or sequence. Such determination can be made by the infusion pump providing therapy or by a separate device that transmits therapy parameters to the infusion pump. In some embodiments, multiple medicaments can be employed in such an ambulatory infusion system as, for example, a first medicament, e.g., insulin, that lowers blood glucose levels and a second medicament, e.g., glucagon, that raises blood glucose levels.

(17) Automated insulin delivery (AID) systems such as those described above can also enable a user to manually program meal boluses of insulin or other medicaments to counteract the rise in blood glucose caused by the consumption of carbohydrates. However, as noted above this can result in “insulin stacking” in such systems if the user delays programming of the meal bolus and the AID system first delivers a correction bolus and/or increases a basal rate in response to the rise in blood glucose caused by the carbohydrates and the user then subsequently programs the meal bolus. Embodiments herein therefore seek to minimize the risk and effect of such insulin stacking and the corresponding risk of dangerously low blood glucose levels.

(18) In embodiments, an AID system can include auto-correction bolus logic that considers insulin or insulin on board from recent automated correction boluses and/or increased basal rates above the open-loop basal rate when calculating meal boluses. In such an embodiment, a meal bolus programmed within a predetermined time of an automated insulin increase is reduced by a predetermined amount based on the previous increase. In embodiments, the predetermined time can be one hour and the decrease can be any percentage of the automated insulin increase (0% to 100%). Such a meal bolus could therefore be calculated according to one or more of equation (1) or equation (2) below, depending on the type of insulin increase:

Meal bolus=(grams of carbohydrates/carbohydrate ratio)–(0-100%*(automated correction bolus value(s) delivered within the past hour)); (1)

Meal bolus=(grams of carbohydrates/carbohydrate ratio)–(0-100%*(basal insulin amount above open loop profile basal rate delivered within the past hour)). (2)

(19) By going back in time to factor in previous increases that may have resulted from ingestion of the same carbohydrates the meal bolus is intended to counteract, the likelihood of insulin stacking is decreased. The predetermined time within which prior automated insulin deliveries are accounted for can alternatively be a time greater than or less than one hour in various embodiments, such as, for example, 15 minutes, 30 minutes, 45 minutes, 1.5 hours, etc. In some embodiments, the percentage of the automated insulin increase by which the meal bolus is decreased can vary by the amount of time that has elapsed since the automated insulin delivery such that when an automated insulin delivery was made more recently a higher percentage of the delivery is reduced from the meal bolus. For example, in one non-limiting example, if an automatic correction bolus was delivered an hour ago, the meal bolus can be reduced by 25% of the

correction bolus whereas if the correction bolus was delivered a half hour ago, the meal bolus can be reduced by 50% given the higher likelihood that a more recent bolus may have resulted from consumption of the meal.

(20) In some embodiments, the decrease in a meal bolus programmed within a predetermined amount of time of an automated insulin delivery increase can further take into account any glucose that would have been burned by insulin independent or insulin dependent pathways over the time since the meal was consumed by utilizing an insulin-on-board decay curve. One example equation that could be employed in such an embodiment is set forth in equation (3) below.

$$\text{Meal bolus} = (\text{grams of carbohydrates/carbohydrate ratio}) * \text{Swan6hrIOB_decay_curve}(\text{time_since_meal}) - \text{IOB} \quad (3)$$

(21) In embodiments, the Swan6hrIOB_decay_curve (time_since_meal) value can equal 100% at time=0 minutes and can equal 0% at time=360 minutes, with a value between 0-100% being applied at all times in between 0-360 minutes based on the IOB decay curve. In such embodiments, the meal bolus value calculated by grams of carbohydrates/carbohydrate ratio is reduced by an amount between 0-100 percent to account for any glucose burned by insulin independent or insulin dependent pathways since the meal. By taking account of the time food has been digesting and blood sugar that has been consumed since the meal was eaten, the likelihood of stacking insulin decreases.

(22) Referring now to FIG. 5, a method **200** of delivering boluses in automated insulin delivery systems according to an embodiment is depicted. At step **202**, the user's pump is operated according to an automated insulin delivery algorithm that automatically delivers insulin to the user based on CGM readings. Automated insulin, such as an automated correction bolus or an automated basal rate increase, is delivered to the user in response to current or predicted future glucose levels at step **204**. The user then programs a meal bolus at step **206**. At step **208**, the system determines if the meal bolus was programmed within a predetermined time (e.g., one hour) of the most recent automated insulin delivery. If the meal bolus was not programmed within the predetermined time of the most recent automated correction bolus, the meal bolus can be delivered as programmed at step **210**. If the meal bolus was programmed within the predetermined time, the meal bolus can be reduced as set forth above to account for the recent automated insulin delivery at step **212**. The modified meal bolus is then delivered at step **214**. Following either meal bolus delivery, the system can then resume delivery insulin according to the AID algorithm.

(23) According to other embodiments, meal boluses programmed within a predetermined time of a previously delivered automated correction bolus can be automatically modified to be delivered over a different time period. Rather than all of the meal bolus being delivered at once, the system can deliver only a portion of the bolus such as, e.g., half of the bolus, upon execution of the bolus command and selectively delay delivery of a second portion of the bolus for a predetermined period of time. In embodiments, after the predetermined time has elapsed, the second portion of the bolus is delivered only if the predicted glucose level of the user is above a minimum threshold. For example, if a meal bolus is programmed within an hour of an automated correction bolus, the system can automatically delay a portion of the bolus for 15 minutes in order to observe the user's glucose levels prior to delivery of the second portion of the bolus. This can ensure that the second portion of the meal bolus is actually needed and the additional carbohydrates in the meal were not already addressed by the previous automated correction bolus to help prevent insulin stacking and potentially lowering the user's glucose to dangerous levels. In embodiments, various time periods can be used for both the time between the automated correction bolus and the meal bolus and the time that the second portion of the meal bolus is delayed, such as, for example, 15 minutes, 30 minutes, 45 minutes, 1 hour, etc. In various embodiments, the first and second portions of the meal bolus can be equal to the total amount of the initially programmed meal bolus or can be a reduced amount of the initially calculated meal bolus based on one or more of the factors discussed herein. In other embodiments, the entire meal bolus can be delayed.

(24) Referring now to FIG. 6, a method **300** of delivering boluses in automated insulin delivery systems according to an embodiment is depicted. As with method **200** described above, the user's pump is operated according to an automated insulin delivery algorithm that automatically delivers insulin to the user based on CGM reading at step **302** and automated insulin is delivered to the user in response to current or predicted future glucose levels at step **304**. After the user programs a meal bolus at step **306**, the system determines if the meal bolus was programmed within a predetermined time of the most recent automated insulin delivery at step **308**. If the meal bolus was not programmed within the predetermined time of the most recent automated correction bolus, the meal bolus can be delivered as programmed at step **310**. If the meal bolus was programmed within the predetermined time, the meal bolus can be modified such that a first portion of the bolus is delivered at step **312**. The system then waits a predetermined period of time to determine if the current or future predicted glucose level of the user is above a threshold at step **314**. If the glucose level is not above the threshold, the second portion of the meal bolus is cancelled at step **316** whereas if the glucose level is above the threshold, the second portion of the meal bolus is then delivered at step **314**. Following delivery of all or a portion of the meal bolus, the system can then resume delivery insulin according to the AID algorithm.

(25) In other embodiments, when a meal bolus is programmed within a predetermined time of an automated correction bolus, rather than modifying the meal bolus the system can instead automatically modify one or more basal rates of the user. For example, the meal bolus is delivered as programmed, but the current basal rate being delivered to the user can automatically be reduced. Alternatively or additionally, a maximum basal rate that the system is allowed to determine and deliver to the user can be reduced during when and after the meal bolus is delivered. In embodiments, such reductions can be for a set period of time such as, e.g., 30 minutes, 1 hour, etc. or can be based on CGM data. For example, the basal rate can be reduced until the CGM data shows stable glucoses levels not at risk of going below a low threshold.

(26) Although the methods described above specifically relate to a system that automatically modifies, e.g., meal boluses programmed within a predetermined time of an automated correction bolus, in other embodiments, the system may only make such modifications if the user provides input into the pump and/or remote control indicating that the user is programming the meal bolus late (i.e., at least 5 minutes after starting the meal).

(27) Although embodiments described herein may be discussed in the context of the controlled delivery of insulin, delivery of other medicaments, singly or in combination with one another or with insulin, including, for example, glucagon, pramlintide, etc., as well as other applications are also contemplated. Device and method embodiments discussed herein may be used for pain medication, chemotherapy, iron chelation, immunoglobulin treatment, dextrose or saline IV delivery, treatment of various conditions including, e.g., pulmonary hypertension, or any other suitable indication or application. Non-medical applications are also contemplated.

(28) With regard to the above detailed description, like reference numerals used therein may refer to like elements that may have the same or similar dimensions, materials, and configurations. While particular forms of embodiments have been illustrated and described, it will be apparent that various modifications can be made without departing from the spirit and scope of the embodiments herein. Accordingly, it is not intended that the invention be limited by the foregoing detailed description.

(29) The entirety of each patent, patent application, publication, and document referenced herein is hereby incorporated by reference. Citation of the above patents, patent applications, publications and documents is not an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these documents.

(30) Modifications may be made to the foregoing embodiments without departing from the basic aspects of the technology. Although the technology may have been described in substantial detail with reference to one or more specific embodiments, changes may be made to the embodiments

specifically disclosed in this application, yet these modifications and improvements are within the scope and spirit of the technology. The technology illustratively described herein may suitably be practiced in the absence of any element(s) not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation and use of such terms and expressions do not exclude any equivalents of the features shown and described or portions thereof and various modifications are possible within the scope of the technology claimed. Although the present technology has been specifically disclosed by representative embodiments and optional features, modification and variation of the concepts herein disclosed may be made, and such modifications and variations may be considered within the scope of this technology.

Claims

1. An ambulatory infusion pump system, comprising: a pump configured to facilitate delivery of insulin to a user; at least one processor functionally linked to the pump, the at least one processor configured to: automatically calculate insulin doses with a closed loop delivery algorithm based on glucose levels of the user; determine that a meal bolus configured to deliver insulin to counteract carbohydrates consumed in a meal should be delivered to the user; determine if the determination to deliver the meal bolus is within a predetermined time of one or more automatically calculated insulin doses that increased an amount of insulin delivered to the user; and automatically modify the meal bolus if the determination to deliver the meal bolus was within the predetermined time of the automatically calculated insulin dose that increased the amount of insulin delivered to the user.
2. The system of claim 1, wherein the at least one processor is configured to determine that a meal bolus configured to deliver insulin to counteract carbohydrates consumed in a meal should be delivered to the user by receiving user input programming a meal bolus.
3. The system of claim 1, wherein the at least one processor is configured to cause the meal bolus to be delivered without modifying the meal bolus if the meal bolus was not determined to be delivered within the predetermined time of an automatically calculated insulin dose that increased the amount of insulin delivered to the user.
4. The system of claim 1, wherein the at least one processor is configured to automatically modify the meal bolus if the meal bolus was programmed within the predetermined time by reducing an amount of the meal bolus.
5. The system of claim 4, wherein the at least one processor is configured to reduce the amount of the meal bolus based on an amount of increase of the one or more automatically calculated insulin doses that increased the amount of insulin delivered to the user.
6. The system of claim 5, wherein the amount of increase of the one or more automatically calculated insulin doses utilized by the at least one processor includes amounts of automatic correction boluses.
7. The system of 5, wherein the amount of increase of the one or more automatically calculated insulin doses utilized by the at least one processor includes basal insulin delivery greater than an open loop basal rate profile.
8. The system of claim 5, wherein the at least one processor is configured to reduce the amount of the meal bolus by a predetermined percentage of the amount of increase of the one or more automatically calculated insulin doses that increased the amount of insulin delivered to the user.
9. The system of claim 8, wherein the predetermined percentage varies based on a time that has elapsed since the one or more automatically calculated insulin doses that increased the amount of insulin delivered to the user.
10. The system of claim 4, wherein the processor is configured to reduce the amount of the meal bolus by delivering a first portion of the meal bolus.
11. The system of claim 10, wherein the processor is configured to deliver a second portion of the

meal bolus after a predetermined period of time only if a glucose level of the user is above a threshold level.

12. The system of claim 4, wherein the processor is configured to reduce the amount of the meal bolus based on an insulin decay curve that accounts for blood glucose burned in the user after the meal was consumed.

13. An ambulatory infusion pump system, comprising: a pump mechanism configured to facilitate delivery of insulin to a user; at least one processor functionally linked to the pump, the at least one processor configured to: determine that a meal bolus configured to deliver insulin to counteract carbohydrates consumed in a meal should be delivered to the user; determine if a closed loop delivery algorithm calculated an increase in insulin based on glucose levels of the user that was delivered within a predetermined time prior to determining that the meal bolus should be delivered; and automatically modify the meal bolus if the increase in insulin based on glucose levels received from the continuous glucose monitor was delivered within the predetermined time of determining that the meal bolus should be delivered.

14. The system of claim 13, wherein the at least one processor is configured to determine that a meal bolus configured to deliver insulin to counteract carbohydrates consumed in a meal should be delivered to the user by receiving user input programming a meal bolus.

15. The system of claim 14, wherein the at least one processor is configured to automatically modify the meal bolus by reducing an amount of the meal bolus if the increase in insulin based on glucose levels received from the continuous glucose monitor was delivered within the predetermined time of determining that the meal bolus should be delivered.

16. The system of claim 15, wherein the at least one processor is configured to reduce the amount of the meal bolus based on an amount of the increase in insulin.

17. The system of claim 16, wherein the amount of the increase in insulin utilized by the at least one processor can include automatic correction boluses and basal insulin delivery greater than an open loop basal rate profile.

18. The system of claim 16, wherein the at least one processor is configured to reduce the amount of the meal bolus by a predetermined percentage of the amount of the increase in insulin.

19. The system of claim 15, wherein the at least one processor is configured to reduce the amount of the meal bolus by delivering a first portion of the meal bolus.

20. The system of claim 19, wherein the at least one processor is configured to deliver a second portion of the meal bolus after a predetermined period of time only if a glucose level of the user is above a threshold level.
